Nov 07, 2024 / 01:30PM GMT
Philippe Martin Viatris Inc-Chief R&D Officer
(Technical difficulty)
Products are focused. Execution on the services pipeline gives us confidence in our ability to continue to grow our base business and address unmet medical need. Fixer is a great example. Last month, we announced positive top-line results that demonstrated the efficacy and safety of a fixer for the treatment of generalized anxiety disorder or GAD Japanese patients with moderate to severe disease. We believe the significant lifecycle opportunity and the potential to be a meaningful treatment option for patients with GAD. The condition, which currently does not have any approved treatment available in Japan, we are targeting to submit an application to the Japanese health authorities in 2025. The growth. Our base business is critical for us to be able to reinvest in our innovative pipeline as we look for opportunities which can make a meaningful difference in patients' lives. We also have a unique opportunity to leverage our global development expertise and broad commercial infrastructure Tech Flex. The
Q3 2024 Viatris Inc Earnings Call Transcript
Nov 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers